Detalhe da pesquisa
1.
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Cancer
; 128(11): 2085-2097, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383908
2.
TP53 Alterations Are Associated With Poor Survival in Patients With Primary Mediastinal Nonseminoma Germ Cell Tumors.
Oncologist
; 27(11): e912-e915, 2022 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36166584
3.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N Engl J Med
; 378(14): 1277-1290, 2018 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29562145
4.
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Cancer
; 126(18): 4156-4167, 2020 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32673417
5.
Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis.
Invest New Drugs
; 38(5): 1601-1604, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31907737
6.
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Lancet Oncol
; 20(12): 1730-1739, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31727538
7.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Lancet Oncol
; 20(10): 1370-1385, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31427204
8.
Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis.
Prostate
; 79(3): 281-287, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30370697
9.
New treatments for stage I testicular cancer.
Clin Adv Hematol Oncol
; 15(8): 626-631, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28949950
10.
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Lancet Oncol
; 17(3): 378-388, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26794930
11.
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Cancer
; 122(3): 411-9, 2016 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26540173
12.
A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCIâ¯9041).
Invest New Drugs
; 34(1): 104-11, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26686201
13.
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Invest New Drugs
; 32(5): 1005-16, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24788563
14.
177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice.
Curr Oncol
; 31(3): 1400-1415, 2024 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38534939
15.
Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.
Cancer
; 119(16): 2999-3006, 2013 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23696129
16.
The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey.
Curr Oncol
; 30(7): 6166-6176, 2023 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37504318
17.
Whole-genome and transcriptome analysis of advanced adrenocortical cancer highlights multiple alterations affecting epigenome and DNA repair pathways.
Cold Spring Harb Mol Case Stud
; 8(3)2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35483882
18.
Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade.
Front Oncol
; 12: 973402, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36176410
19.
Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients.
Clin Genitourin Cancer
; 20(3): 210-218, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35115252
20.
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
Eur J Cancer
; 171: 124-132, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717820